(Q46140918)

19 December 2017

title

Targeting immunosuppressive adenosine in cancer (English)

1 reference

19 December 2017

4

Mark J Smyth

1 reference

19 December 2017

author name string

Dipti Vijayan

series ordinal

1

1 reference

19 December 2017

Arabella Young

series ordinal

2

1 reference

19 December 2017

Michele W L Teng

series ordinal

3

1 reference

19 December 2017

language of work or name

English

0 references

publication date

23 October 2017

1 reference

19 December 2017

published in

Nature Reviews Cancer

1 reference

19 December 2017

volume

17

1 reference

19 December 2017

issue

12

1 reference

19 December 2017

page(s)

709-724

1 reference

19 December 2017

https://scigraph.springernature.com/pub.10.1038/nrc.2017.86

exact match

0 references

cites work

Immunological mechanisms of the antitumor effects of supplemental oxygenation

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The histological structure of some human lung cancers and the possible implications for radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Accumulation of purine catabolites in solid tumors exposed to therapeutic hyperthermia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Extracellular adenosine triphosphate and adenosine in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine A2A receptor as a drug discovery target

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

A2A adenosine receptor protects tumors from antitumor T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Ligand-Independent Adenosine A2B Receptor Constitutive Activity as a Promoter of Prostate Cancer Cell Proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Impairment of adenosine A3 receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73-adenosine: a next-generation target in immuno-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Targeting cancer-derived adenosine: new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Host A(2B) adenosine receptors promote carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Inhibition of CD39 enzymatic function at the surface of tumor cells alleviates their immunosuppressive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Role of TGF-β signaling in generation of CD39+CD73+ myeloid cells in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD39 Expression Identifies Terminally Exhausted CD8+ T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Disordered purinergic signaling inhibits pathological angiogenesis in cd39/Entpd1-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73-deficient mice are resistant to carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Extracellular adenosine-mediated modulation of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Blockade of A2b adenosine receptor reduces tumor growth and immune suppression mediated by myeloid-derived suppressor cells in a mouse model of melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Myeloid-derived suppressor cells contribute to A2B adenosine receptor-induced VEGF production and angiogenesis in a mouse melanoma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Metabolic Reprogramming of Immune Cells in Cancer Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Protective role of hypoxia-inducible factor-1α-dependent CD39 and CD73 in fulminant acute liver failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

HIF-dependent induction of adenosine A2B receptor in hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Cyclic AMP Represents a Crucial Component of Treg Cell-Mediated Immune Regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

MicroRNA-128b suppresses tumor growth and promotes apoptosis by targeting A2bR in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

IL-1 beta and TNF-alpha regulation of the adenosine receptor (A2A) expression: differential requirement for NF-kappa B binding to the proximal promoter

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Immunogenic cell death in cancer and infectious disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 is associated with poor prognosis in high-grade serous ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Expression of ecto-5'-nucleotidase (eN, CD73) in cell lines from various stages of human melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine receptors and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Vascular CD39/ENTPD1 directly promotes tumor cell growth by scavenging extracellular adenosine triphosphate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Anti-CD73 therapy impairs tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Overexpression of CD73 in prostate cancer is associated with lymph node metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Lymphatic transport of exosomes as a rapid route of information dissemination to the lymph node.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 engagement promotes lymphocyte binding to endothelial cells via a lymphocyte function-associated antigen-1-dependent mechanism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Regulatory circuits of T cell function in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Targeting natural killer cells in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Agonistic CD40 mAb-Driven IL12 Reverses Resistance to Anti-PD1 in a T-cell-Rich Tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD4(+) T cell anergy prevents autoimmunity and generates regulatory T cell precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Peripheral adenosine A2A receptors are involved in carrageenan-induced mechanical hyperalgesia in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Hypoxia-adenosinergic immunosuppression: tumor protection by T regulatory cells and cancerous tissue hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages - a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Mesenchymal stromal cells derived from cervical cancer produce high amounts of adenosine to suppress cytotoxic T lymphocyte functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine A2B receptor blockade slows growth of bladder and breast tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine receptors in regulation of dendritic cell differentiation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 is associated with poor prognosis in HNSCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

TNF-alpha upregulates adenosine 2b (A2b) receptor expression and signaling in intestinal epithelial cells: a basis for A2bR overexpression in colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Hypoxia-induced secretion of TGF-β1 in mesenchymal stem cell promotes breast cancer cell progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Transforming Growth Factor-β Signaling Guides the Differentiation of Innate Lymphoid Cells in Salivary Glands

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

TP53 mutations in human cancers: origins, consequences, and clinical use

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

High expression of CD73 as a poor prognostic biomarker in human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Extracellular adenosine sensing-a metabolic cell death priming mechanism downstream of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Targeting CD73 in the tumor microenvironment with MEDI9447.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Ecto-ATPase CD39 Inactivates Isoprenoid-Derived Vγ9Vδ2 T Cell Phosphoantigens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Extracellular generation of adenosine by the ectonucleotidases CD39 and CD73 promotes dermal fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Extracellular purines, purinergic receptors and tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/ENTPD1 null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma Model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

NAD+-metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD39 and CD73 in immunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The NAD(+) salvage pathway modulates cancer cell viability via p73.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Prostatic acid phosphatase, a neglected ectonucleotidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Consequences of the lack of CD73 and prostatic acid phosphatase in the lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Soluble ecto-5'-nucleotidase (5'-NT), alkaline phosphatase, and adenosine deaminase (ADA1) activities in neonatal blood favor elevated extracellular adenosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Extracellular adenosine regulates naive T cell development and peripheral maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Oncology meets immunology: the cancer-immunity cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine A2A receptor is involved in cell surface expression of A2B receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Adenosine down-regulates the surface expression of dipeptidyl peptidase IV on HT-29 human colorectal carcinoma cells: implications for cancer cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Activation of the A2B adenosine receptor in B16 melanomas induces CXCL12 expression in FAP-positive tumor stromal cells, enhancing tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Expression and clinical significance of CD73 and hypoxia-inducible factor-1α in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The expression and clinical significance of CD73 molecule in human rectal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

CD73 Predicts Favorable Prognosis in Patients with Nonmuscle-Invasive Urothelial Bladder Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Loss of CD73-mediated actin polymerization promotes endometrial tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Ecto-5'-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Generation of anti-inflammatory adenosine byleukocytes is regulated by TGF-β

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Ectonucleoside triphosphate diphosphohydrolase-1 (E-NTPDase1/CD39) as a new prognostic marker in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.86

7 January 2021

inferred from DOI database lookup

Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors

1 reference

12 December 2020

Overexpression of CD39 and high tumoral CD39⁺/CD8⁺ ratio are associated with adverse prognosis in resectable gastric cancer

1 reference

12 December 2020

Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice

1 reference

12 December 2020

Crosstalk between adenosine receptor (A2A isoform) and ERalpha mediates ethanol action in MCF-7 breast cancer cells.

1 reference

12 December 2020

The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine

1 reference

12 December 2020

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2017.86

1 reference

19 December 2017

Dimensions Publication ID

1092350988

0 references

Fatcat ID

release_gcwoc5yairgvlmojo32dkpv24e

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/gcwoc5yairgvlmojo32dkpv24e

24 November 2022

mapped directly with Wikidata item

1 reference

19 December 2017